- Investigator-led Phase IIa study met its primary endpoint of disease control rate at 12 weeks -
BERGEN, Norway, June 5, 2023 - BerGenBio ASA , a clinical-stage biopharmaceutical company. | June 5, 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA, JAPAN, AUSTRALIA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION. | May 26, 2023
Bergen - Reference is made to the stock exchange announcement published by BerGenBio ASA on 25 April 2023, regarding a proposed partially underwritten rights issue of shares with preferential. | May 22, 2023
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE S REPUBLIC OF CHINA OR JAPAN OR ANY. | May 20, 2023
BERGENBIO ASA - Terms of the partially underwritten rights issue NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED. | May 20, 2023